Detection of therapeutically targetable mutations in NSCLC:

Webinar presenters, Ed Schuuring, PhD, Professor of Molecular, Oncological Pathology, University Medical Center Groningen, and Darryl Irwin, PhD, Vice President, Scientific Affairs, Agena Bioscience, discuss the clinical applications of circulating cell free DNA (ccfDNA) in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors or immune checkpoint inhibitors, the characteristics of a suitable diagnostic-grade platform required for the detection of tumor-specific mutations with high sensitivity in ccfDNA, the UltraSEEK® Lung panel for the detection of the most common predictive markers in comparison to other circulating tumor DNA (ctDNA) detection assays for NSCLC, and the utility of ctDNA as a minimally invasive molecular tool to guide treatment decisions and disease monitoring, especially when no appropriate tumor tissue biopsy is available.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY.
This on-demand webinar originally broadcast October 13, 2021.